Millstone Evans Group LLC Invests $69,000 in Solventum Co. (NYSE:SOLV)

Millstone Evans Group LLC purchased a new stake in Solventum Co. (NYSE:SOLV) in the 4th quarter, HoldingsChannel reports. The firm purchased 1,045 shares of the company’s stock, valued at approximately $69,000.

A number of other large investors also recently bought and sold shares of SOLV. MRP Capital Investments LLC raised its position in Solventum by 93.9% during the fourth quarter. MRP Capital Investments LLC now owns 10,275 shares of the company’s stock worth $679,000 after acquiring an additional 4,975 shares during the period. Investment House LLC increased its stake in shares of Solventum by 111.3% during the fourth quarter. Investment House LLC now owns 76,171 shares of the company’s stock worth $5,032,000 after purchasing an additional 40,130 shares in the last quarter. Xponance Inc. raised its position in shares of Solventum by 9.8% during the 4th quarter. Xponance Inc. now owns 21,014 shares of the company’s stock worth $1,388,000 after purchasing an additional 1,879 shares during the last quarter. Boston Partners purchased a new position in Solventum in the 4th quarter valued at about $110,378,000. Finally, Generali Asset Management SPA SGR acquired a new stake in Solventum in the 4th quarter worth about $659,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Morgan Stanley raised their price objective on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th. The Goldman Sachs Group upped their target price on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Piper Sandler raised their price target on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. Finally, Bank of America upped their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, February 26th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $79.86.

Solventum Stock Performance

NYSE:SOLV opened at $74.00 on Monday. The company’s 50-day moving average is $75.17 and its two-hundred day moving average is $71.61. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The firm has a market capitalization of $12.80 billion and a price-to-earnings ratio of 26.91.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.